Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Children's Hospital, Translational Genomics Research Institute, and University of Arizona.
"Be the change you wish to see in the world..." Gandhi
“It is every man's obligation to put back into the world at least the equivalent of what he takes out of it.”
— Albert Einstein
For decades, a deadly type of childhood cancer has eluded science’s best tools. Now doctors have made progress with an unusual treatment: Dripping millions of copies of a virus directly into kids’ brains to infect their tumors and spur an immune system attack.
A team of researchers at Fralin Biomedical Research Institute at VTC and City of Hope, a comprehensive care center, believes the complex way fluid flows through glioblastoma tumors holds the key to the therapy's success.
SynNotch-CAR T cell therapy is able to precisely target glioblastoma brain tumors.
For decades, a deadly type of childhood cancer has eluded science's best tools. Now doctors have made progress with an unusual treatment: dripping millions of copies of a virus directly into children's brains to infect their tumors and spur an immune system attack.
As a non-invasive treatment for select brain tumors and brain metastases, SRS is a well-studied and proven procedure that often provides equivalent or superior outcomes to surgery. Unlike surgery however, radiosurgery requires no incision and is painless.
Research led by scientists at Children's Cancer Institute and published this week in the international journal, Cell Reports, offers an exciting new therapeutic approach for the treatment of DIPG by using a new anti-cancer drug. The new drug, CBL0137, is an anti-cancer compound developed from the antimalarial drug quinacrine.
